Enterprise Value
-140M
Cash
219.5M
Avg Qtr Burn
-18.97M
Short % of Float
6.22%
Insider Ownership
16.23%
Institutional Own.
56.54%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KB-0742 (CDK9 Inhibitor) Details Solid tumor/s | Phase 1/2 Data readout | |
Lanraplenib (SYK Inhibitor) +gilteritinib Details Blood cancer, Leukemia, Acute myeloid leukemia, Cancer | Phase 1/2 Data readout | |
Entospletinib (SYK Inhibitor) Details HOXA9/MEIS1-high AML (Acute myeloid leukemia) | Failed Discontinued |